Please login to the form below

Not currently logged in
Email:
Password:

BlackThorn Therapeutics appoints CEO

Gregory Vontz joins from Topica Pharmaceuticals

BlackThorn Therapeutics Gregory VontzSan Francisco, US-based biotech BlackThorn Therapeutics has appointed Gregory Vontz as its new chief executive officer.

Vontz brings over 30 years of biotech and pharma industry experience to the role, joining from fungal infection specialist Tropica Pharmaceuticals where he also served as chief executive.

Prior to this, Vontz was president and chief operating officer of Connetics Corporation, spent 12 years in a series of senior marketing and product development roles at Genentech, and worked in sales and sales management at Merck & Co.

Dr Mark Corrigan, chairman of the board at BlackThorn, said: “On behalf of the Board and the BlackThorn team, I am pleased to welcome Greg as our new chief executive officer.

“His experience as a biotech executive, record of successful drug development and strategic transactions will serve BlackThorn well in advancing the company's mission to develop new treatments for patients suffering from neurobehavioral disorders.”

17th February 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics